Patent · US Active

Methods for the prevention and treatment of hearing loss using Oseltamivir

US12053446B1 · kind B1 · utility

0Cited by

0References

4Claims

0Family size

Assignees

Ting Theropeutics, Inc. · US
St. Jude Children's Research Hospital, Inc. · US

Inventors

Tal Teitz · Omaha, US
Jian Zuo · Beijing, CN
Taosheng Chen · Germantown, US

Key dates

Filing date	Mar 31, 2023
Grant date	Aug 6, 2024
Priority date	—
Expiry date	Mar 31, 2043

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P27/16
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Oseltamivir is used as active agent to treat a hearing impairment and to prevent a hearing impairment, and a method of treating and/or preventing hearing impairments or disorders using Oseltamivir are disclosed. Oseltamivir exhibits excellent protection against noise-induced hearing loss and against cisplatin-induced hearing loss.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.